Johnson & Johnson drug faces limited Europe ban
European pharmaceutical regulators are considering banning the use of Johnson & Johnson's anemia drug, Eprex, for a major class of patients because it is linked to a rare but serious side effect,
European pharmaceutical regulators are considering banning the use of Johnson & Johnson's anemia drug, Eprex, for a major class of patients because it is linked to a rare but serious side effect,